BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld MedTech
Home
» Antegenes raises $2.4M in seed round to scale genetic testing for cancer risk in EU
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Antegenes raises $2.4M in seed round to scale genetic testing for cancer risk in EU
Aug. 19, 2022
By
Bernard Banga
No Comments
Antegenes OÜ raised $2.4 million in seed funding to deploy its genomic testing for personalized cancer prevention in new markets across Europe.
BioWorld MedTech
Financings
Private
Seed
Europe